RIZE Clinical Trial for Individuals with Hyperinsulinism



Subscribe to be notified of changes or updates to this page.

3 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Our team is working on a clinical drug trial that involves giving you a study drug that is not FDA-approved called RZ358. The goal of the trial is to test the study drug safety, how your body processes the drug, how the drug affects your body, and see if it can increase your blood sugar. If you agree to take part, your participation will last for up to 27 weeks and include 4 weeks of screening, 8 weeks of treatment, and a 15 week follow-up period. It is possible that treatment with the study drug infusions may improve your blood sugar levels and/or reduce the use of other medication(s) to prevent hypoglycemia. For more information, contact us at hiresearch@chop.edu.

Eligibility & Criteria

IRB #:
Official Title:
An Open-Label Multiple-Dose Study of RZ358 in Patients with Congenital Hyperinsulinism
Study Phase:
Phase II
Eligible Age Range:
12 - 45 Years
Study Categories: